65,437 trials
Primary Prevention of Sudden Cardiac Arrest · Secondary Prevention of Sudden Cardiac Arrest
Primary: Percentage of Participants Not Experiencing a System or Procedure Related Complication Through 5-years — 98.9 Percentage of participants
Lymphoma · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Maximum Tolerated Dose (MTD) — 20; 100 milligrams
Influenza · Vaccine
Primary: Number of Participants With Solicited Local Reactions Within 7 Days Following Each Vaccination — 10; 2; 0; 11 Participants
Melanoma
Primary: Overall Response Rate (ORR) as Defined by RECIST v1.1 at Week 18 — 20; 56 percentage of participants
Hodgkin's Lymphoma · Non-Hodgkin's Lymphoma
Primary: Number of Patients Able to Proceed to Transplant — 16; 13; 1; 0 Participants
Multiple Myeloma · Non-Hodgkin's Lymphoma
Primary: Percent of Patients Who Mobilize and Collect at Least Half of the Total Target CD34+ Cell Dose in the First Apheresis — 32.0; 58.3 percentage of participants
Metastatic Osteosarcoma · Recurrent Osteosarcoma · Refractory Osteosarcoma
Primary: Disease Control Rate (Cohort I) — 1 participants
Stroke · Motor Function
Primary: Changes in Motor Function (Jebsen-Taylor Task) — -214.33; -50.16; -117.98 seconds
Cervical Cancer
Primary: Percentage of Participants With at Least 1 Treatment Emergent Adverse Event (TEAE) — 100; 100 percentage of participants
Cancer, Solid Tumor
Primary: Number of Participants Experiencing Dose-limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Pneumococcal Disease
Primary: Percentage of Participants With Local Reactions Within 10 Days After Vaccination — 7.9; 2.5; 8.6; 12.7 percentage of participants
Pharmacological Action
Primary: The Frequency of Hypoglycaemic Episodes With Sitagliptin vs Placebo Treatment. — 5.35; 5.72 Hypoglycaemic episodes
Solid Tumor and Hematologic Malignancies
Primary: Clinical Benefit Rate (CBR) for Solid Tumors at Week 16 as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 23.1 Percentage of participants
Oral Cancer
Primary: Number of Participants With no Residual Tumor Following Photodynamic Therapy (PDT) — 22 Participants
Arthropathy Shoulder
Primary: Patient Pain Scores — 4.0; 2.8 score on a scale — p=.0197